Latest news from Provectus Biopharmaceuticals, Inc on News en-us Copyright 2025 News 115 31 / /images/newswise-logo-rss.gif /articles/late-melanoma-patients-will-need-several-lines-of-therapy-intralesional-treatment-promising-says-new-paper/?sc=rsin /articles/late-melanoma-patients-will-need-several-lines-of-therapy-intralesional-treatment-promising-says-new-paper/?sc=rsin Thu, 12 Feb 2015 08:00:00 EST Despite advances in melanoma treatment, many patients with advanced melanoma will need several lines of therapy according to a recent paper in Current Opinion in Oncology. Provectus Biopharmaceuticals, Inc /articles/rose-bengal-and-co-inhibitory-blockade-improve-anti-tumor-immunity-melanoma-regression/?sc=rsin /articles/rose-bengal-and-co-inhibitory-blockade-improve-anti-tumor-immunity-melanoma-regression/?sc=rsin Wed, 03 Dec 2014 07:00:00 EST Clinical trials have shown that a preparation of rose bengal called PV-10 has induced regression of both injected lesions and uninjected bystander lesions in patients with melanoma, and tumor ablation with PV-10 has been shown to increase certain T-cell populations in patients' peripheral blood. Provectus Biopharmaceuticals, Inc /articles/novel-rose-bengal-formulation-obliterates-lesions-in-patients-with-deadliest-of-melanomas/?sc=rsin /articles/novel-rose-bengal-formulation-obliterates-lesions-in-patients-with-deadliest-of-melanomas/?sc=rsin Tue, 30 Sep 2014 13:05:00 EST A formulation of the dye, rose bengal, which has been around for more than a century, has recently been shown to have promise in patients with cutaneous melanoma, one of the deadliest forms of the disease. Provectus Biopharmaceuticals, Inc